More on PMN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $11.72 |
|
|||
| Open | $11.72 | ||||
| 52 Wk High | $0.05 | ||||
| 52 Wk Low | $0.05 | ||||
| Day High | $11.72 | ||||
| Day Low | $11.72 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 236,156 | ||||
- Form 8-K ProMIS Neurosciences For: Jul 28
- ProMIS reports no ARIA-E in interim Alzheimer's drug trial data
- ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
- ProMIS to host webinar on Alzheimer's drug trial interim data
- ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
- Chardan Starts ProMIS Neurosciences (PMN) at Buy
- H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)
- ProMIS reports human evidence of PMN310 reducing amyloid-beta oligomers
- ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
- Roth/MKM Starts ProMIS Neurosciences (PMN) at Buy
Entities mentioned with PMN
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- FDA | View Related Stories »
- S1 | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
